These are the stocks posting the largest moves before the bell.Market Insiderread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
Retailers could be in for a jolly jump in holiday sales despite headwinds like the U.S.-China trade war and threat of another economic slowdown.Retailread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
Apple isn't trying to blow our minds with groundbreaking new features on the iPhone 11, but is making lots of little improvements each year, this year focusing on cameras and...Technologyread more
The move is the latest sign of the blurring boundaries between big tech and big finance amid challenges for both industries.Financeread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
Pizza Hut is also talking with Kellogg and other suppliers about the plant-based meat trend.Restaurantsread more
Saudi Arabia's defense spending is the world's third-largest — behind the U.S. and China, says Gary Grappo, former U.S. ambassador to Oman.Energyread more
Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump’s criticism of pharmaceutical giant Pfizer is having an impact on how other companies in health care set their prices.
“By putting pressure on one particular company, I think all the companies are saying: We don’t want to be Pfizer,” Denner said in an exclusive video for CNBC PRO. “Even if they maybe raise prices in a different way – if they typically raise prices in a different way or do it on a different subset of products, they’re going to be thinking twice.”
The investor’s comments came less than 10 days after Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies . For its part, Pfizer raised the price of 41 drugs by as much as 9 percent, though it also lowered prices on five drugs by as much as 44 percent.
In a statement, Pfizer defended itself and argued that the price adjustments only affected a minor portion of the company’s extensive portfolio of treatments. The company's stock fell 0.2 percent Monday, but is up 2.9 percent since January; is up 5 percent year to date.
"Our portfolio includes more than 400 medicines and vaccines; we are modifying prices for approximately 10 percent of these, including some instances where we’re decreasing the price," Pfizer said in a statement. "Importantly, list prices do not reflect what most patients or insurance companies pay.”
Denner, a Carl Icahn protege, is known for his shareholder activism in the biotechnology and pharmaceutical industries. Through Sarissa, he currently has active stakes in Biogen, Ironwood Pharmaceuticals and The Medicines Company.
Sarissa oversees $535 million in assets under management according to its latest Form ADV filing.
Click here to see the full video, but you must be a CNBC Pro subscriber.